Endocare To Shed Non-Core Assets, Focus On Cryocare Indications
This article was originally published in The Gray Sheet
Executive Summary
Endocare is divesting "certain non-core" assets in order to concentrate resources on expanding adoption of its Cryocare prostate cancer platform and pursuit of additional applications
You may also be interested in...
People In Brief
Cordis appointments: Johnson & Johnson interventional cardiology division has filled three VP-level positions, the firm said Oct. 13. Carl St. Bernard joins Cordis as VP of U.S. sales and marketing. He was previously general manager of the magnetic resonance imaging unit at GE Healthcare. Paul Chang has moved from J&J's pharmaceutical R&D team to become Cordis' VP-worldwide clinical research and operations. Finally, Ryan Saadi, formerly of Genzyme, is tapped to fill the health economics and reimbursement VP role. A Cordis spokesperson would not comment on progress in filling two other high-level positions for worldwide president and chief medical officer previously reported to be vacant (1"The Gray Sheet" June 23, 2008, p. 8)
People In Brief
Cordis appointments: Johnson & Johnson interventional cardiology division has filled three VP-level positions, the firm said Oct. 13. Carl St. Bernard joins Cordis as VP of U.S. sales and marketing. He was previously general manager of the magnetic resonance imaging unit at GE Healthcare. Paul Chang has moved from J&J's pharmaceutical R&D team to become Cordis' VP-worldwide clinical research and operations. Finally, Ryan Saadi, formerly of Genzyme, is tapped to fill the health economics and reimbursement VP role. A Cordis spokesperson would not comment on progress in filling two other high-level positions for worldwide president and chief medical officer previously reported to be vacant (1"The Gray Sheet" June 23, 2008, p. 8)
Endocare CEO
Craig Davenport fills post, vacant since Paul Mikus'April resignation, following disclosure that the SEC had launched an investigation into the cryosurgical and stent technology firm's accounting practices (1"The Gray Sheet" April 14, 2003, p. 27). Davenport formerly served as a consultant to Endocare's board of directors and as CEO of the DW Group, a private healthcare advisory and investment firm...